Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect of Azvudine Treatment: a Retrospective Cohort Study

Fifth Affiliated Hospital, Sun Yat-Sen University4,201 enrolled

Overview

The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.

4201 COVID-19 patients discharged from our hospital were enrolled. Binary logistic regression analysis and ROC curve were used to investigate the role of comorbidities, laboratory parameters and clinical manifestation on progression of COVID-19 patients. We used propensity-score models conditional on baseline characteristics and Univariate Cox regression model to examine whether Azvudine can reduce the mortality of COVID-19 patients.

Study Type

OBSERVATIONAL

Enrollment

4,201

Conditions

COVID-19

Interventions

AzvudineDRUG

Received antiviral treatment with azvudine

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: The COVID-19 positive patients Exclusion Criteria: 1. patients treated with both azvudine and monotamivir; 2. patients receiving other antiviral drugs such as nematavir/ritonavir; 3. age \< 18 years old

Locations (1)

The Fifth Affiliated Hospital of Sun Yat-sen University

Zhuhai, Guangdong, China

Outcomes

Primary Outcomes

All-cause mortality of COVID-19 patients

Time frame: Time from onset to death

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.